Literature DB >> 26659639

Multilocus Inherited Neoplasia Alleles Syndrome: A Case Series and Review.

James Whitworth1, Anne-Bine Skytte2, Lone Sunde2, Derek H Lim3, Mark J Arends4, Lisa Happerfield5, Ian M Frayling6, Rick van Minkelen7, Emma R Woodward8, Marc D Tischkowitz1, Eamonn R Maher1.   

Abstract

Mendelian causes of inherited cancer susceptibility are mostly rare and characterized by variable expression and incomplete penetrance. Phenotypic variability may result from a range of causes including locus heterogeneity, allelic heterogeneity, genetic and environmental modifier effects, or chance. Another potential cause is the presence of 2 or more inherited cancer predisposition alleles in the same individual. Although the frequency of such occurrences might be predicted to be low, such cases have probably been underascertained because standard clinical practice has been to test candidate inherited cancer genes sequentially until a pathogenic mutation is detected. However, recent advances in next-generation sequencing technologies now provide the opportunity to perform simultaneous parallel testing of large numbers of inherited cancer genes. Herein we provide examples of patients who harbor pathogenic mutations in multiple inherited cancer genes and review previously published examples to illustrate the complex genotype-phenotype relationships in these cases. We suggest that clinicians should proactively consider the likelihood of this phenomenon (referred to herein as multilocus inherited neoplasia alleles syndrome [MINAS]) in patients with unusual inherited cancer syndrome phenotypes. To facilitate the clinical management of novel cases of MINAS, we have established a database to collect information on what is likely to be an increasingly recognized cohort of such individuals.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26659639     DOI: 10.1001/jamaoncol.2015.4771

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  22 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

2.  Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.

Authors:  Caroline Goehringer; Christian Sutter; Matthias Kloor; Johannes Gebert; Emily P Slater; Monika Keller; Irmgard Treiber; Petra Ganschow; Martina Kadmon; Ute Moog
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

3.  Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.

Authors:  Rachel Silva-Smith; Daniel A Sussman
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

4.  The simplest explanation does not have to be preferred: co-occurrence of pathogenic variants in cancer-predisposing genes.

Authors:  Sergi Castellví-Bel
Journal:  Eur J Hum Genet       Date:  2022-01-04       Impact factor: 4.246

5.  Clinical implications of genetic testing in familial intermediate and late-onset colorectal cancer.

Authors:  Malene Djursby; Thomas van Overeem Hansen; Karin A W Wadt; Majbritt Busk Madsen; Lukas Adrian Berchtold; Charlotte Kvist Lautrup; Sara Markholt; Uffe Birk Jensen; Lotte Nylandsted Krogh; Malene Lundsgaard; Anne Marie Gerdes; Mef Nilbert; Christina Therkildsen
Journal:  Hum Genet       Date:  2022-07-29       Impact factor: 5.881

6.  Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.

Authors:  Ido Laish; Eitan Friedman; Gili Levi-Reznick; Inbal Kedar; Lior Katz; Zohar Levi; Naama Halpern; Shani Parnasa; Aasem Abu-Shatya; Elizabeth Half; Yael Goldberg
Journal:  Breast Cancer Res Treat       Date:  2021-06-04       Impact factor: 4.872

7.  Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.

Authors:  Hagit Shani; Rinat Bernstein-Molho; Yael Laitman; Iris Netzer; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2021-01-15       Impact factor: 4.872

8.  Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.

Authors:  Georgios N Tsaousis; Eirini Papadopoulou; Konstantinos Agiannitopoulos; Georgia Pepe; Nikolaos Tsoulos; Ioannis Boukovinas; Theofanis Floros; Rodoniki Iosifidou; Ourania Katopodi; Anna Koumarianou; Christos Markopoulos; Konstantinos Papazisis; Vasileios Venizelos; Achilleas Kapsimalis; Grigorios Xepapadakis; Amanda Psyrri; Eugeniu Banu; Dan Tudor Eniu; Alexandru Blidaru; Dana Lucia Stanculeanu; Andrei Ungureanu; Vahit Ozmen; Sualp Tansan; Mehmet Tekinel; Suayib Yalcin; George Nasioulas
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

9.  Familial wild-type gastrointestinal stromal tumour in association with germline truncating variants in both SDHA and PALB2.

Authors:  James Whitworth; Ruth T Casey; Philip S Smith; Olivier Giger; Jose Ezequiel Martin; Graeme Clark; Jaqueline Cook; Marlee S Fernando; Phillipe Taniere; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2021-04-15       Impact factor: 4.246

10.  Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers.

Authors:  Yoon Young Choi; Su-Jin Shin; Jae Eun Lee; Lisa Madlensky; Seung-Tae Lee; Ji Soo Park; Jeong-Hyeon Jo; Hyunki Kim; Daniela Nachmanson; Xiaojun Xu; Sung Hoon Noh; Jae-Ho Cheong; Olivier Harismendy
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.